Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroko Bando

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Cancer Science|October 8, 2024
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumorsTomomi Nishimura, Ravi Velaga, Norikazu Masuda, et al.
Leukemia|November 27, 2023
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolutionSakurako Suma, Yasuhito Suehara, Manabu Fujisawa, et al.
Breast (Edinburgh, Scotland)|November 13, 2022
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort studyMasataka Sawaki, Naruto Taira, Yukari Uemura, et al.
Breast Cancer (Tokyo, Japan)|May 23, 2022
Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC)Akemi Kataoka, Takayuki Ueno, Hideko Yamauchi, et al.
Breast Cancer (Tokyo, Japan)|May 20, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancerTetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, et al.
Breast Cancer (Tokyo, Japan)|June 23, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancerTetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, et al.
Nature Cell Biology|March 25, 2022
A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodellingYoshiaki Abe, Mamiko Sakata-Yanagimoto, Manabu Fujisawa, et al.
British Journal of Cancer|January 18, 2024
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patientsDon Pietro Saldajeno, Shinpei Kawaoka, Norikazu Masuda, et al.
Cancer Cell|July 4, 2025
Distinct follicular T cell subsets regulate lymphoma progression and outcomesYoshiaki Abe, Junko Zenkoh, Akinori Kanai, et al.
Journal of Cancer|October 2, 2023
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 StudyHirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Cancer Science|October 8, 2024
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumorsTomomi Nishimura, Ravi Velaga, Norikazu Masuda, et al.
Leukemia|November 27, 2023
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolutionSakurako Suma, Yasuhito Suehara, Manabu Fujisawa, et al.
Breast (Edinburgh, Scotland)|November 13, 2022
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort studyMasataka Sawaki, Naruto Taira, Yukari Uemura, et al.
Breast Cancer (Tokyo, Japan)|May 23, 2022
Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC)Akemi Kataoka, Takayuki Ueno, Hideko Yamauchi, et al.
Breast Cancer (Tokyo, Japan)|May 20, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancerTetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, et al.
Breast Cancer (Tokyo, Japan)|June 23, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancerTetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, et al.
Nature Cell Biology|March 25, 2022
A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodellingYoshiaki Abe, Mamiko Sakata-Yanagimoto, Manabu Fujisawa, et al.
British Journal of Cancer|January 18, 2024
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patientsDon Pietro Saldajeno, Shinpei Kawaoka, Norikazu Masuda, et al.
Cancer Cell|July 4, 2025
Distinct follicular T cell subsets regulate lymphoma progression and outcomesYoshiaki Abe, Junko Zenkoh, Akinori Kanai, et al.
Journal of Cancer|October 2, 2023
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 StudyHirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, et al.
Pageof 13